George Simeon's Form 4 filing
CRISPR Therapeutics AG (CRSP) · filed Jul 17, 2025
- Accession no.
- 0000950170-25-096666
- Filed
- Jul 17, 2025
- Trade date
- Jul 16, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $51.5M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| George SimeonCIK 0001595117 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 16, 2025 | Common Shares | PPurchaseAcquired | +6,510 | $52.03 | +$338,715.3 | 69,687 | Indirect | |
| Jul 16, 2025 | Common Shares | PPurchaseAcquired | +22,319 | $52.03 | +$1,161,257.57 | 238,897 | Indirect | |
| Jul 16, 2025 | Common Shares | PPurchaseAcquired | +960,983 | $52.03 | +$49,999,945.49 | 1,730,179 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.